Aridis Pharmaceuticals Receives Award from the Cystic Fibrosis Foundation Therapeutics to Advance Panaecin™

Aridis Pharmaceuticals, Inc., a biopharmaceutical company applying proprietary technologies to produce novel
anti-infectives and immunotherapies for infectious diseases, announced today it has secured a therapeutics development award from Cystic Fibrosis Foundation Therapeutics (CFFT), the drug discovery and development affiliate of the Cystic Fibrosis Foundation, the world’s leader in the search for a cure for cystic fibrosis (CF). The award will support the development of Panaecin™ (gallium citrate), Aridis’ development-stage therapeutic candidate aimed at treating life-threatening lung infections, through Phase 2a clinical trials in CF patients. Aridis will also benefit from close collaboration with CFFT’s Therapeutics Development Network, the largest CF clinical trials network in the world, which will assist in trial design and execution, and facilitate access to clinical trial sites.

This entry was posted in Recent Development News: Q1 - 2017, Recent Developments. Bookmark the permalink.
Read Full Article »